Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
parabacteroides goldsteinii outer membrane vesicles
- Development stage
- Preclinical
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Oral, Subcutaneous
01
Overview
Parabacteroides goldsteinii outer membrane vesicles (Pg-OMVs) are a preclinical biologic therapeutic derived from the gut commensal bacterium *Parabacteroides goldsteinii*. These nanoscale extracellular vesicles contain bioactive components and have demonstrated immunomodulatory activity. In preclinical models, Pg-OMVs administered orally or subcutaneously can travel to inflamed tissues and suppress inflammation. The mechanism of action involves the suppression of neutrophil extracellular trap (NET) formation through activation of the Cav-1-Nrf2 signaling axis, modulation of inflammatory cytokines (such as downregulating IL-23/Th17 signaling), and regulation of bile acid metabolism. [1, 4, 7, 10] It is being investigated for inflammatory conditions including rheumatoid arthritis, psoriasis, and acute lung injury. [4, 10] Currently, it is an experimental compound with no identified commercial developer.
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)CAV1 (Caveolin-1)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)
Beyond the preview
Go deeper on parabacteroides goldsteinii outer membrane vesicles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on parabacteroides goldsteinii outer membrane vesicles.